ArticleMicrobiologyOpen2025
Evaluation of Colistin Susceptibility in Carbapenem-Resistant Acinetobacter baumannii Isolates Using Broth Microdilution, MICRONAUT-MIC-Strip, and VITEK MS.
Article in MicrobiologyOpen, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
We aimed to analyze the colistin susceptibility using broth microdilution (BMD) and commercially available MICRONAUT-MIC-Strip (MMS) test and VITEK MS in carbapenem-resistant Acinetobacter baumannii (CRAB) isolates. Colistin susceptibility of 194 CRAB isolated from various clinical specimens between December 2020 and 2022 was determined by BMD and commercial MMS method. Minimum inhibitory concentrations of the commercial method were compared with the standard BMD. In the second part of the study, colistin susceptibility of the isolates was tested using the MALDIxin method, which detects modified lipid A, by VITEK MS, MALDI-TOF MS (bioMérieux, France). The presence of mcr-1-5 genes in resistant isolates was investigated using in-house multiplex polymerase chain reaction. Of these, 23 (11.8%) were found to be colistin resistant, whereas 171 (88.2%) isolates were susceptible. MMS categorical agreement was found to be 98.9% and essential agreement was 96.3%. The major error was found to be 1.03%, whereas a very major error was not detected. The MALDIxin test developed according to VITEK MS did not detect mutations responsible for lipopolysaccharide-induced colistin resistance in our isolates (expected peak at 1935-2033 m/z). The mcr-1-5 genes were not detected in our isolates. The MMS test is a reliable alternative method for the detection of colistin susceptibility in CRAB. Colistin resistance of the isolates used in our study was not associated with lipid A modification. Alternative mechanisms, such as efflux pumps, are a possibility. To our knowledge, this is the first VITEK MS-based method that enables rapid detection of colistin resistance in negative ion mode, and further studies are needed to determine colistin resistance in this way.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.